The Effect of Topical Anesthetic Using Lidocaine 2.5%/Prilocaine 2.5% Versus Lidocaine 7%/Tetracaine 7% Cream on Patients' Pain and Operative Experience During Treatment With QSwitched 532nm Laser

Status: Active, not recruiting
Location: See location...
Intervention Type: Drug, Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study will conduct a split-face and -body randomized control trial to compare lidocaine 2.5%/prilocaine 2.5% topical anesthetic (LPTA), lidocaine 7%/tetracaine 7% topical anesthetic (LTTA), and placebo vechicle (PV) on patients' pain perceptions with Q-switched 532nm laser for the treatment of lentigines and/or photorejuvenation.Subjects will fill out a pain score on a visual analog scale (VAS) with 0 being no pain and 10 being most pain after each treatment area is completed.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 25
Maximum Age: 65
Healthy Volunteers: Accepts Healthy Volunteers
View:

• Patients who have moderate lentigines and/or photodamage and desire laser toning.

• Females 25-65 years of age.

• In good health.

• Have Fitzpatrick phototype I-III.

• Willingness and the ability to understand and provide informed consent and communicate with the investigator/study staff.

Locations
United States
Illinois
Northwestern University Feinberg School of Medicine, Department of Dermatology
Chicago
Time Frame
Start Date: April 2015
Estimated Completion Date: December 2022
Participants
Target number of participants: 48
Treatments
Active Comparator: lidocaine 2.5%/prilocaine 2.5% topical anesthetic
Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
Active Comparator: lidocaine 7%/tetracaine 7% topical anesthetic
Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
Placebo Comparator: placebo vehicle
Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
Authors
Sponsors
Leads: Northwestern University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials